Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Pharmacopeia has licensed from Bristol-Myers Squibb a selective androgen receptor modulator program, including a lead non-steroidal compound in Phase I clinical development and back-up compounds, which was designed to provide the benefits of testosterone without its unwanted side effects on the prostate.
Subscribe to our email newsletter
In consideration for the selective androgen receptor modulator (SARM) program license, Pharmacopeia will apply a portion of its medicinal chemistry resources to an unrelated Bristol-Myers Squibb discovery program for up to three years and pay Bristol-Myers Squibb milestone payments associated with submission and approval of a therapeutic product for marketing and a stepped royalty on net sales of therapeutic SARM products, if any, resulting from the SARM development program.
Les Browne, president and CEO, said: “I am very pleased to have broadened our portfolio under mutually attractive terms by adding Phase I compound, PS178990, which is the seventh clinical development-stage compound being advanced by Pharmacopeia or its collaborators. This program offers Pharmacopeia another opportunity to build the business by adding a Phase I development stage product candidate with the potential to treat a wide range of underserved conditions.”